## DR. KENT CBD GLUCOSAMINE CREAM



Ingredients: AQUA, CAPRYLIC/CAPRIC TRIGLICERIDE, STEARIC ACID, COCO-CAPRYLATE/-CAPRATE, PERSEA GRATISSIMA OIL, DIMETHYL SULFONE, CETEARYL ALCOHOL, SODIUM CETEARYL SULFATE, GLYCERYL STEARATE, SQUALENE, MENTHOL, CAMPHOR, CANNABIS SATIVA LEAF EXTRACT, SODIUM CHONDROTIN SULFATE, SORBITAN CAPRYLATE, PROPANEDIOL, BENZOIC ACID, GLUCOSAMINE SULFATE, EUGENIA CARYOPHYLLUS FLOWER OIL, CAPISCIUM FRUTESCENS FRUIT EXTRACT, METHYL SALICILATE, ROSMARINUS OFFICINALIS EXTRACT, EUGENOL, ISOEUGENOL



HEMP EXTRACT Cannabis sativa L.



GLUCOSAMINE SULFATE Glucosamine sulfate



MENTHOL Mentha × piperita



CAMPHOR *Camphor* 





## CERTIFICATE OF ANALYSIS No.: 2023-11271

Work order:

Analysis ID:

Method ID:

## CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

## SAMPLE \*

Sample ID:

Sample type:

Batch No.: \*

**CBD DR KENT CREAM - GLUCOSAMINE** 

2307027

KCG01123046A

Cream





Sample received: 15/02/2023 Start of analysis: 15/02/2023 End of analysis: Analyst: Janja Ahej

16/02/2023

\* Information provided by the client.

Sample condition: SUITABLE

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	< LOQ	n/a	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	< LOQ	n/a	
CBD	- Cannabidiol	1.141	0.057	
тнсу	- Tetrahydrocannabivarin	< LOQ	n/a	
CBN	- Cannabinol	< LOQ	n/a	
∆ <sup>9</sup> -THC	- Δ-9-Tetrahydrocannabinol	0.0414	0.0091	
∆ <sup>8</sup> -THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
СВС	- Cannabichromene	0.0319	0.0070	-
∆ <sup>9</sup> -THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBE	- Cannabielsoin	< LOQ #	n/a	·····
CBV	- Cannabivarin	< LOQ #	n/a	
CBCA	- Cannabichromenic acid	< LOQ #	n/a	
СВТ	- Cannabicitran	< LOQ #	n/a	

2023-107307

PHL RPC 16C

2023 035

Method SOP: MET-LAB-003-02

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

16/02/2023

End of Certificate

Approved by:

mag. Janja Ahej Analytical Laboratory Manager

Authorized by: Ant

dr. Boštjan Jančar Chief Technology Officer